By Dr. Lilian Massihi, MD, Board-Certified Family Medicine, Advanced BHRT Certification
GLP-1 receptor agonist medications, including semaglutide and tirzepatide, are producing real results for many patients. But among women in perimenopause and menopause, a consistent pattern keeps showing up in both clinical practice and published research. The medication works, but not as well as expected. Appetite suppresses. The scale moves. And then the visceral fat around the abdomen stays stubborn, energy never fully recovers, and results plateau well before the goal.
A 2026 Mayo Clinic-led study, published in The Lancet Obstetrics, Gynaecology, & Women’s Health, offered a significant part of the explanation. Postmenopausal women who were on both hormone therapy and tirzepatide lost about 35% more weight than women on tirzepatide alone. The hormone therapy group averaged 19.2% body weight reduction. Women not on hormone therapy averaged 14.0%.
That is not a marginal difference. And it raises a direct question for any woman in perimenopause or menopause whose GLP-1 results have disappointed her: has anyone evaluated your hormones?
What the Research Now Shows About Hormone Therapy and GLP-1 Weight Loss
The 2026 Mayo Clinic study is the most rigorous look to date at the hormone therapy and tirzepatide combination in postmenopausal women. Researchers reviewed outcomes from 120 participants with overweight or obesity who received tirzepatide for 12 months or more, comparing those on hormone therapy to similar women without it.
The finding of roughly 35% greater relative weight loss in the hormone therapy group was consistent with emerging biological evidence about how estrogen and GLP-1 interact. Because this was an observational study rather than a randomized trial, the researchers were careful to note that they cannot confirm hormone therapy directly caused the additional weight loss. Women on hormone therapy may also have had better sleep, more energy, and greater consistency with diet and activity, all of which are downstream effects of hormonal stability.
That nuance does not weaken the implication. It expands it. If hormone therapy improves sleep, reduces cortisol-driven fat accumulation, restores insulin sensitivity, and increases the responsiveness of GLP-1 receptors in the brain, then every one of those pathways is a reason the combination outperforms GLP-1 alone. The mechanism explains the outcome, and the outcome matches what the mechanism would predict.
If your prescribing physician never evaluated your hormonal status before or alongside your GLP-1 prescription, an important variable was left unaddressed.
Why Estrogen Affects How GLP-1 Medications Work in Your Body
GLP-1 receptor agonists work through three primary pathways: slowing gastric emptying, suppressing appetite through the central nervous system, and improving insulin sensitivity. That third mechanism, insulin sensitivity, is where the interaction with estrogen becomes clinically important.
Estrogen regulates glucose metabolism directly. It supports cellular responsiveness to insulin, reduces inflammation in fat tissue, and maintains the metabolic signaling that determines whether the body stores or burns fat. When estrogen declines during perimenopause and menopause, insulin resistance increases. The body becomes less responsive to glucose signals. Fat accumulates, particularly in the abdomen, and weight loss becomes harder at any caloric intake.
GLP-1 medications work to restore insulin sensitivity. But they are doing that work in a hormonal environment that is simultaneously eroding it. Preclinical research suggests that estrogen may also enhance the responsiveness of GLP-1 receptors in the brain, meaning adequate estrogen could make the appetite-suppressing effect of these medications more effective. The practical consequence of insufficient estrogen is a blunted response to the very mechanism the medication relies on.
Restoring estrogen does not replace the GLP-1 mechanism. It restores the environment in which that mechanism can function as designed.
Perimenopause Is the Weight Loss Problem GLP-1 Alone Was Never Designed to Solve
To understand why hormones matter this much to GLP-1 outcomes, it helps to understand what perimenopause weight gain actually is at a biological level.
It begins with progesterone, the first hormone to decline in perimenopause, often years before estrogen shifts significantly. Progesterone interacts with GABA receptors in the brain, producing a calming, sleep-deepening effect. When progesterone falls, sleep quality degrades: difficulty falling asleep, waking at 2 or 3 in the morning, a nervous system that will not quiet even when the body is exhausted. Poor sleep chronically elevates cortisol. Elevated cortisol signals the body to store fat preferentially in the abdomen, and at the same time worsens the insulin resistance that makes weight loss harder.
When estrogen then begins its own decline, it shifts fat distribution from the hips and thighs toward the abdomen, reduces metabolic flexibility, and further degrades the insulin signaling that GLP-1 medications are designed to support.
By the time a perimenopausal woman reaches for a GLP-1 medication, she may be working against several compounding mechanisms at once: progesterone-driven sleep disruption, cortisol-driven visceral fat accumulation, estrogen-driven insulin resistance, and the metabolic consequences of all three interacting over months or years.
GLP-1 medications address appetite and insulin sensitivity directly. They were not designed to address progesterone deficiency, cortisol dysregulation, or the hormonal shifts that drive the underlying metabolic environment. Hormone optimization addresses what GLP-1 cannot. That is not a criticism of GLP-1 medications. It is a description of the gap they were never built to fill.
What Hormone Optimization Alongside GLP-1 Therapy Looks Like
Hormone optimization is not a prescription to add to a stack. It is a physician-directed clinical program built around your individual hormonal profile: what is deficient, how your body is responding, and what your personal and family history indicates about the safest approach forward.
At AllureMD, the evaluation includes:
- Progesterone status, addressed first, because progesterone falls first. Its effects on sleep, cortisol, and visceral fat accumulation are the foundation of the metabolic picture.
- Estrogen levels, evaluated in the context of fat distribution, insulin sensitivity signals, and cardiovascular markers, not just reference ranges.
- Thyroid function, frequently overlooked. Hypothyroidism produces symptoms that closely overlap with both perimenopause and GLP-1 side effects, and untreated thyroid insufficiency blunts weight loss.
- Cortisol patterns and adrenal load. Chronically elevated cortisol is a direct driver of abdominal fat that hormone optimization can address.
- Fasting insulin and metabolic markers, to establish a baseline and measure response.
Treatment is bioidentical, molecularly identical to what your body produces, and titrated to how you respond rather than to where a reference range sets the floor. Progesterone is prescribed to all women who need it, not only those with a uterus, because its benefits for sleep, mood, and metabolic stability are independent of uterine status.
The goal is not to replace what a GLP-1 medication does. It is to restore the hormone optimization your metabolism needs to respond fully to every other health investment you are making.
The Long-Term Case: Beyond the Number on the Scale
The 35% weight loss difference attracted the headlines. But the long-term case for hormone optimization alongside any weight-focused intervention extends well past body composition.
Large observational research has linked early hormone therapy to lower fracture risk and reduced rates of osteoporosis in postmenopausal women. The North American Menopause Society’s 2022 position statement supports hormone therapy initiation for appropriate candidates within the first decade after menopause onset, citing cardiovascular benefit and improved lipid profiles among the documented advantages.
The clinical conversation about hormone therapy has shifted. In November 2025, the FDA announced the removal of the longstanding black box warning from menopausal hormone therapy products, with the updated labeling taking effect in February 2026, reflecting a revised reading of the evidence on risks and benefits. The question now is whether that information has reached the patients who need it most.
If you are investing in your metabolic health through GLP-1 medication, and no one has yet evaluated your hormonal status, that is the conversation worth having next.
Frequently Asked Questions
Does hormone therapy cause weight gain?
Bioidentical hormone therapy, when properly titrated, is not associated with weight gain. The concern most women have heard comes from older studies using synthetic hormones and synthetic progestins, not bioidentical estradiol and progesterone. Many women find that restoring hormonal balance supports rather than undermines weight management, which is consistent with both the mechanism and the research.
Can I be on hormone therapy and a GLP-1 medication at the same time?
This is a physician-directed decision based on your individual health profile, current medications, and goals. There is no general contraindication, and the emerging research suggests potential benefit from the combination. The right path is a comprehensive evaluation, not a prescription added to an existing protocol without clinical oversight.
Why didn’t my GLP-1 prescriber mention hormones?
Most providers prescribing GLP-1 medications, including primary care, endocrinology, and weight management clinics, are not specialists in hormone optimization and may not evaluate hormonal status as part of that workup. The two areas frequently operate independently. Bringing them into view together requires a physician who evaluates the full metabolic and hormonal picture at once.
Will hormone therapy help if I’m postmenopausal, not just perimenopausal?
The Mayo Clinic study specifically evaluated postmenopausal women, and the broader research on bone protection, cardiovascular benefit, and GLP-1 interaction spans the full menopausal spectrum. Timing and formulation of hormone therapy differ depending on when you initiate relative to your last menstrual period, which is one reason to work with a physician who specializes in hormone optimization rather than a generalist.
How does AllureMD approach GLP-1 therapy?
GLP-1 therapy is a physician-directed clinical decision that AllureMD evaluates as part of a comprehensive metabolic assessment for appropriate candidates. Every treatment recommendation is made by Dr. Massihi after a thorough review of your health history, labs, symptoms, and goals. We do not prescribe any therapy, including GLP-1, without a complete evaluation.
AllureMD is a physician-led hormone optimization practice in Madison, Mississippi. Dr. Lilian Massihi, MD evaluates each patient’s complete hormonal picture before making any recommendation. To schedule your consultation, book a complimentary discovery call.
About the Author
Dr. Lilian Massihi, MD is a board-certified family medicine physician and hormone optimization specialist who completed her undergraduate education at UCLA, earned her medical degree at the University of Poznań, and finished her residency at the University of Mississippi Medical Center. For more than five years, she practiced as a hospitalist, treating patients in the late stages of cardiovascular disease, cognitive decline, and severe osteoporosis. She kept asking the same question: what would have been different if someone had intervened sooner? That question led her to bioidentical hormone therapy, where a rigorous review of the evidence changed the direction of her career. She founded AllureMD in Madison, Mississippi to practice the kind of medicine she had come to believe in: treating the entire hormonal system, titrating to how patients actually feel, with a physician leading every decision.